Clinical trial
An Open-Label, Single-Dose, Parallel-Group, Two-Part Study to Evaluate the Pharmacokinetics and Safety of Risdiplam in Subjects With Mild or Moderate Hepatic Impairment Compared to Subjects With Normal Hepatic Function
NCT03920865 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-Label, Single-Dose, Parallel-Group, Two-Part Study to Evaluate the Pharmacokinetics and Safety of Risdiplam in Subjects With Mild or Moderate Hepatic Impairment Compared to Subjects With Normal Hepatic Function
- Lead sponsor
- Hoffmann-La Roche
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- May 16, 2019
- Completion date
- January 2, 2020
- Enrollment
- 26 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.